156 related articles for article (PubMed ID: 37018649)
1. Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in
Stahler A; Hoppe B; Na IK; Keilholz L; Müller L; Karthaus M; Fruehauf S; Graeven U; Fischer von Weikersthal L; Goekkurt E; Kasper S; Kind AJ; Kurreck A; Alig AHS; Held S; Reinacher-Schick A; Heinemann V; Horst D; Jarosch A; Stintzing S; Trarbach T; Modest DP
J Clin Oncol; 2023 Jun; 41(16):2975-2987. PubMed ID: 37018649
[TBL] [Abstract][Full Text] [Related]
2. Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in
Modest DP; Karthaus M; Fruehauf S; Graeven U; Müller L; König AO; Fischer von Weikersthal L; Caca K; Kretzschmar A; Goekkurt E; Haas S; Kurreck A; Stahler A; Held S; Jarosch A; Horst D; Reinacher-Schick A; Kasper S; Heinemann V; Stintzing S; Trarbach T
J Clin Oncol; 2022 Jan; 40(1):72-82. PubMed ID: 34533973
[TBL] [Abstract][Full Text] [Related]
3. Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212).
Heinrich K; Karthaus M; Fruehauf S; Graeven U; Mueller L; König AO; von Weikersthal LF; Caca K; Kretzschmar A; Goekkurt E; Haas S; Alig AHS; Kurreck A; Stahler A; Held S; Sommerhäuser G; Heinemann V; Stintzing S; Trarbach T; Modest DP
ESMO Open; 2023 Aug; 8(4):101568. PubMed ID: 37441876
[TBL] [Abstract][Full Text] [Related]
4. Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212).
Stahler A; Kind AJ; Sers C; Mamlouk S; Müller L; Karthaus M; Fruehauf S; Graeven U; Fischer von Weikersthal L; Sommerhäuser G; Kasper S; Hoppe B; Kurreck A; Held S; Heinemann V; Horst D; Jarosch A; Stintzing S; Trarbach T; Modest DP
Clin Cancer Res; 2024 Apr; 30(7):1256-1263. PubMed ID: 38289994
[TBL] [Abstract][Full Text] [Related]
5. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
Stintzing S; Wirapati P; Lenz HJ; Neureiter D; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Al-Batran S; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Modest DP; Jung A; Kirchner T; Aderka D; Tejpar S; Heinemann V
Ann Oncol; 2019 Nov; 30(11):1796-1803. PubMed ID: 31868905
[TBL] [Abstract][Full Text] [Related]
6. Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Sommerhäuser G; Kurreck A; Beck A; Fehrenbach U; Karthaus M; Fruehauf S; Graeven U; Mueller L; Koenig AO; V Weikersthal LF; Goekkurt E; Haas S; Stahler A; Heinemann V; Held S; Alig AHS; Kasper S; Stintzing S; Trarbach T; Modest DP
Eur J Cancer; 2023 Jan; 178():37-48. PubMed ID: 36399909
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial.
Ballhausen A; Karthaus M; Fruehauf S; Graeven U; Müller L; König AO; von Weikersthal LF; Sommerhäuser G; Alig AHS; Goekkurt E; Meyer-Knees JW; Kurreck A; Stahler A; Held S; Kasper S; Heinrich K; Heinemann V; Stintzing S; Trarbach T; Modest DP
Eur J Cancer; 2023 Sep; 190():112955. PubMed ID: 37454537
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212).
Sommerhäuser G; Karthaus M; Kurreck A; Ballhausen A; Meyer-Knees JW; Fruehauf S; Graeven U; Mueller L; Koenig AO; Weikersthal LFV; Goekkurt E; Haas S; Stahler A; Heinemann V; Held S; Alig AHS; Kasper-Virchow S; Stintzing S; Trarbach T; Modest DP
Int J Cancer; 2024 Mar; 154(5):863-872. PubMed ID: 37840339
[TBL] [Abstract][Full Text] [Related]
9. Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials.
Raimondi A; Nichetti F; Stahler A; Wasan HS; Aranda E; Randon G; Kurreck A; Meade AM; Díaz-Rubio E; Niger M; Stintzing S; Palermo F; Trarbach T; Prisciandaro M; Sommerhäuser G; Fisher D; Morano F; Pietrantonio F; Modest DP
Eur J Cancer; 2023 Sep; 190():112945. PubMed ID: 37441940
[TBL] [Abstract][Full Text] [Related]
10. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
Carrato A; Abad A; Massuti B; Grávalos C; Escudero P; Longo-Muñoz F; Manzano JL; Gómez A; Safont MJ; Gallego J; García-Paredes B; Pericay C; Dueñas R; Rivera F; Losa F; Valladares-Ayerbes M; González E; Aranda E;
Eur J Cancer; 2017 Aug; 81():191-202. PubMed ID: 28633089
[TBL] [Abstract][Full Text] [Related]
11. Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation.
Lonardi S; Rasola C; Lobefaro R; Rossini D; Formica V; Scartozzi M; Frassineti GL; Boscolo G; Cinieri S; Di Donato S; Pella N; Bergamo F; Raimondi A; Arnoldi E; Antonuzzo L; Granetto C; Zustovich F; Ronzoni M; Leo S; Morano F; Loupakis F; Buggin F; Zagonel V; Fassan M; Cremolini C; Boni L; Pietrantonio F;
J Clin Oncol; 2023 Dec; 41(34):5263-5273. PubMed ID: 37535876
[TBL] [Abstract][Full Text] [Related]
12. Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial).
Stahler A; Heinemann V; Schuster V; Heinrich K; Kurreck A; Gießen-Jung C; Fischer von Weikersthal L; Kaiser F; Decker T; Held S; Graeven U; Schwaner I; Denzlinger C; Schenk M; Neumann J; Kirchner T; Jung A; Kumbrink J; Stintzing S; Modest DP
Eur J Cancer; 2021 Nov; 157():71-80. PubMed ID: 34507244
[TBL] [Abstract][Full Text] [Related]
13. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
[TBL] [Abstract][Full Text] [Related]
14. FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314).
Modest DP; Karthaus M; Kasper S; Moosmann N; Keitel V; Kiani A; Uhlig J; Jacobasch L; Fischer V Weikersthal L; Fuchs M; Kaiser F; Lerchenmüller C; Sent D; Junghanß C; Held S; Lorenzen S; Kaczirek K; Jung A; Stintzing S; Heinemann V
Eur J Cancer; 2022 Sep; 173():297-306. PubMed ID: 35970102
[TBL] [Abstract][Full Text] [Related]
15. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
16. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
Schwartzberg LS; Rivera F; Karthaus M; Fasola G; Canon JL; Hecht JR; Yu H; Oliner KS; Go WY
J Clin Oncol; 2014 Jul; 32(21):2240-7. PubMed ID: 24687833
[TBL] [Abstract][Full Text] [Related]
17. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
[TBL] [Abstract][Full Text] [Related]
18. Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With
Rossini D; Antoniotti C; Lonardi S; Pietrantonio F; Moretto R; Antonuzzo L; Boccaccino A; Morano F; Brugia M; Pozzo C; Marmorino F; Bergamo F; Tamburini E; Passardi A; Randon G; Murgioni S; Borelli B; Buonadonna A; Giordano M; Fontanini G; Conca V; Formica V; Aglietta M; Bordonaro R; Aprile G; Masi G; Boni L; Cremolini C
J Clin Oncol; 2022 Sep; 40(25):2878-2888. PubMed ID: 35666229
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
20. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
